Churg-Strauss vasculitis and idiopathic hypereosinophyl syndrome: Role of molecular biology in the differential diagnosis of hypereosinophyl syndrome;Vasculite di Churg-Strauss e sindrome ipereosinofila idiopatica: Ruolo della biologia molecolare nella diagnosi differenziale delle sindromi ipereosinifile

Reumatismo

Volumn 60, Issue 2, 2008, Pages 120-124

  Pugliese, Nausica ^a   Bruzzone, M ^a   Della Rossa, A ^a   Baldini, C ^a   Catarsi, E ^a   Tavoni, A ^a   d'Ascanio, A ^a   Bombardieri, S ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Anti neutrophyl cytoplasmic antibodies (ANCA); Churg Strauss; Hypereosinophilic syndrome; Molecular biology; Vasculitis

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EOSINOPHILIA; FEMALE; HUMAN; HYPEREOSINOPHILIC SYNDROME; MALE; MOLECULAR BIOLOGY; SCREENING TEST; BLOOD; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; CHURG-STRAUSS SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MIDDLE AGED; MOLECULAR BIOLOGY; PROSPECTIVE STUDIES;

EID: 55249105737     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000; 7: 21-4.
2. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1- PDGFR kinase in hypereosinophilic sindrome and chronic eosinophilic leukemia. Curr Opin Hematol 2004; 11: 51-7.
3. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27.
4. Kallenberg, Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and Clinical significance of Anti neutrophil citoplasmic antibodies (ANCA) in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926-35.
5. Muschen M, Wasrkulat U, Perniok A, Even J, Moers C, Kismet B, et al. Involvement of soluble CD 95 in Churg-Strauss syndrome. Am J Pathol 1999; 155: 915-25.
6. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology criteria for the classification of Churg-Strauss (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-2000.
7. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis and polyarteritis nodosa. Am J Pathol 1951; 27: 277-301.
8. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759-79.
9. Hellmich B, Ehlers S, Csernok S, Gross WL. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003; Suppl 32: S69-S75.
10. Manganelli P, Fietta P, Carotti M, Pesci A, Salaffi F. Respiratory system involvement in systemic vasculitides. Clin Exp Rheumatol 2006; 24 (2 Suppl 41): S48-59.
11. Jennette JC, Falk RJ. The role of pathology in the diagnosis of systemic vasculitis. Clin Exp Rheumatol 2007; 25 (1 Suppl 44): S52-6.
12. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19: 25-32.
13. Hellmich B, Holl-Ulrich K, Merz H, Gross WL. [Hypereosinophilic syndrome and Churg-Strauss syndrome: is it clinically relevant to differentiate these syndromes?] Internist (Berl) 2008; 49: 286-96.
14. Simon HU, Cools J. Novel approaches to therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27: 519-27.
15. Schapira D, Nahir AM, Hadad N. Interferon-induced Raynaud's syndrome. Semin Arthritis Rheum 2002; 32: 157-62.